Latest Product Pipeline News

Broken Hill Mines Limited reports outstanding high-grade silver-lead-zinc intercepts alongside promising gold-copper mineralisation at its Pinnacles Mine, expanding its phase 1 drilling program and targeting near-term open pit operations.

Invex Therapeutics Ltd has had its trading suspension lifted following the announcement of a material acquisition, signaling a pivotal moment for the biotech company.

Clover Corporation posted a robust 38% revenue increase to $86 million in FY25, driven by product innovation and operational gains, while declaring a final dividend. The company’s cautious outlook for FY26 reflects ongoing regulatory and production challenges.

ReNerve Limited has launched its Empliq tissue product range in the US, marking a strategic expansion into the growing dermal and amniotic tissue market. The launch complements its existing nerve repair portfolio and sets the stage for further growth.

Catalyst Metals Limited has doubled its gold reserves to 1.5 million ounces as of June 2025, setting the stage to ramp up production to 200,000 ounces per year over the next decade.

Resolute Mining has announced a significant 28% increase in the gold resource at its Doropo project in Côte d’Ivoire, boosting the total to 4.4 million ounces and setting the stage for an extended mine life beyond the initial plan.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.

Spacetalk Ltd reported a transformative FY25 with a 25% increase in annual recurring revenue and a significant narrowing of losses, underpinned by strong subscriber growth and a strategic debt restructuring.

BCAL Diagnostics has launched its first commercial breast cancer diagnostic test, BREASTESTplus™, in Australia, marking a key milestone despite a $7.24 million loss for FY2025. The company is also advancing its US operations with a new subsidiary and clinical trials underway.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

LTR Pharma Limited (ASX, LTP) reported significant progress in FY25, advancing its novel intranasal treatments for erectile dysfunction and expanding its commercial footprint in Australia and the US. The company secured key partnerships and capital raises, positioning itself for regulatory milestones and global market entry.

Jatcorp Limited reported a $6.9 million net loss for FY25, hit by a trademark dispute in China that suspended key product sales. Despite setbacks, the company is accelerating new channel growth and product innovation to regain momentum.